An observational study in Chronic Kidney Disease and Type 2 Diabetes Mellitus, sponsored by Bayer. Active, not recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Bayer · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Renal Insufficiency, Chronic by Bayer — 4 open to participants now, 8 under way, 2 of them phase 3. Renal Insufficiency, Chronic · Bayer.
Among the 49 studies in Renal Insufficiency, Chronic by Bayer, this one is the 14th largest by enrollment of the 17 observational ones that give a count, is one of 3 that started in 2025, is one of 17 observational ones, and was the 45th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →4 of the 49 studies in Renal Insufficiency, Chronic by Bayer are open now, in 12 countries. Recruiting first, the newest first:
Bayer · Sites in Spain
Ages 18+
Bayer · Sites in United States, Germany, Japan and 1 more country
Ages 18+
Bayer · Sites in United States, Argentina, Australia and 29 more countries
Ages 1–18
Bayer · Sites in Mexico
Ages 18+
By country, each count listing its studies:
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 529 is above the median of 213 across 835 observational studies indexed under Renal Insufficiency, Chronic.
Median enrollment 98 across the 32 interventional studies, 4,613 across the 17 observational. Of the 39 that completed or were terminated, 4 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
4 of the studies in Renal Insufficiency, Chronic by Bayer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT06763146BayerAn Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice | 2026-11-30 |
| NCT06278207BayerAn Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions | 2027-09-30 |
| NCT07232537BayerAn Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 49 studies in Renal Insufficiency, Chronic by Bayer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an observational study in which data from people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone are collected and studied.
Chronic kidney disease is a long-term condition where the kidneys gradually lose their ability to filter waste and extra water from the blood. Type 2 diabetes occurs when the body does not produce enough insulin or does not use it effectively, leading to high blood sugar levels that can harm the kidneys. As a result, CKD can develop as a complication of T2D.
The study drug, finerenone, is already approved for doctors to prescribe to patients with CKD and T2D.
Finerenone is a medication that works by blocking certain proteins known as mineralocorticoid receptors. An increased stimulation of these proteins is thought to damage the kidneys and the heart. By lowering their stimulation, finerenone reduces the risk of kidney disease progressively getting worse.
The main purpose of this study is to learn more about characteristics and treatment patterns of people with CKD and T2D who have recently started or will start finerenone treatment as prescribed by their doctor as part of their routine medical care in South Korea.
The FINE-REAL Korea study is designed to collect additional data on people with CKD and T2D who are treated with finerenone according to the approved product information, and it will work alongside the original FINE-REAL study (NCT05348733) to gather enough information for safety assessments in Korean population.
To achieve this, researchers will collect data on:
The study will also monitor any medical problems (known as adverse events) that participants may experience during the study. All adverse events will be recorded, regardless of whether they are related to the treatment.
One specific concern is hyperkalemia, which refers to high potassium levels in the blood. This condition can occur when finerenone is used with certain blood pressure medications. Researchers want to understand how often hyperkalemia happens and whether it leads to:
Data for this study will be collected from medical records and through interviews conducted by study doctors during routine medical visits.
Participants will be involved in the study for up to 12 months, although this duration may be shorter if their finerenone treatment is stopped early.
Participants with a diagnosed of CKD and T2D will be enrolled after the decision for treatment with finerenone has been made by the treating physician.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who are newly prescribed finerenone under routine treatment conditions.
Drug: Kerendia (Finerenone, BAY94-8862)
Decision will be taken by the treating physician to initiate treatment with finerenone.
Descriptive analysis of clinical characteristics of participants with chronic kidney disease (CKD) and with type 2 diabetes (T2D)
Time frame: Up to 12 months after start of finerenone
Descriptive summary of reasons for introducing finerenone
Time frame: Up to 12 months after start of finerenone
Descriptive summary of reasons for discontinuation of finerenone
Time frame: Up to 12 months after start of finerenone
Planned and actual duration of treatment with finerenone
Time frame: Up to 12 months after start of finerenone
Planned and actual dosing of finerenone
Time frame: Up to 12 months after start of finerenone
Descriptive summary of secondary therapies used in participants with CKD and T2D
Time frame: Up to 12 months after start of finerenone
Occurrence of adverse events (AEs)
Including treatment emergent adverse events (TEAEs), adverse drug reactions (ADRs), unexpected AEs, unexpected ADRs, serious adverse events (SAEs), and serious adverse drug reactions (SADRs)
Time frame: Up to 30 days after the final treatment with finerenone
Occurrence of hyperkalemia
Reported hyperkalemia leading to permanent study drug discontinuation, dialysis or hospitalization
Time frame: Up to 30 days after the final treatment with finerenone
Plan to share: No — Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Sep 2027, 22 months after the start.
Of 51 industry-sponsored observational studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 51. This study's planned 22 months is below that.
Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →